| Literature DB >> 25928421 |
Cristina Taddei1, Roberto Gnesotto2, Silvia Forni2, Guglielmo Bonaccorsi3, Andrea Vannucci2, Giorgio Garofalo4.
Abstract
OBJECTIVE: To estimate the effects of cycling promotion on major non-communicable diseases (NCDs) and costs from the public healthcare payer's perspective.Entities:
Mesh:
Year: 2015 PMID: 25928421 PMCID: PMC4415918 DOI: 10.1371/journal.pone.0125491
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Cycling and NCD prevention data.
| Age- and sex-standardised incidence rate per 100,000 | HR among regular commuter cyclists | Time needed for health benefits to build up | |
|---|---|---|---|
|
| 760; Bonora et al. 2004 [ | 0.64 (95% CI: 0.45–0.92); Hu et al. 2003 [ | 5 years; WHO/Europe HEAT for cycling [ |
|
| 276.3; Regional Health Agency of Tuscany, 2006–2008 [ | 0.82 (95% CI: 0.71–0.95); Hoevenaar-Bloom et al. 2011 [ | 5 years; WHO/Europe HEAT for cycling [ |
|
| 275.5; Regional Health Agency of Tuscany, 2006–2008 [ | 0.82 (95% CI: 0.71–0.95); Hoevenaar-Bloom et al. 2011 [ | 5 years; WHO/Europe HEAT for cycling [ |
Literature data: Active commuting and NCD prevention.
| Active commuting and NCD prevention | Study design & Methods | Study population | Year data were collected & Setting | Results | Reference |
|---|---|---|---|---|---|
|
| Prospective cohort study; To assess the association between specific types of physical activity (occupational, commuting, leisure-time) and type 2 diabetes incidence. | 6,898 men; 7,392 women | 1982, 1987, 1992 | Adjusted Hazard Ratio of type 2 diabetes incidence for walking or cycling to work: | Hu et al. 2003 [ |
| Random sex-age stratified population sample. | Aged 35–64; 48% male | Finland | 1–29 min: 0.96 (0.74–1.25) | ||
| Self-administered questionnaire: medical history, socioeconomic factors, physical activity (occupational, commuting, leisure-time), and smoking; Physical examination: BMI, systolic blood pressure. | (Eastern and southwestern regions, Helsinki capital area) | ≥ 30 min: 0.64 (0.45–0.92) | |||
| Baseline surveys with cohorts in 1982, 1987, 1992, participation rate 74–88%; Mean follow-up period 12 years. | Adjustment: age, sex, study year, other types of physical activity (both occupational and leisure-time), education, systolic blood pressure, smoking, BMI. | ||||
|
| Prospective cohort study; To assess the association between specific types of physical activity (walking, gardening, cycling, and sports) and cardiovascular disease incidence (myocardial infarction, angina pectoris, and stroke). | 7,451 men; 8,991 women | 1994–1997 | Adjusted Hazard Ratio of CVD incidence for cycling: | Hoevenaar-Bloom et al. 2011 [ |
| Random sex-age stratified population sample. | Aged 20–65; 45% male | The Netherlands | 0.82 (0.71–0.95) | ||
| Self-reported physical activity (EPIC/MORGEN questionnaire). Survey’s questionnaire: physical activity (leisure time, commuting, sports, and occupational), educational level, smoking, alcohol consumption, CVD risk factor medication; Physical examination: BMI, cholesterol (total and HDL), systolic blood pressure. | (Doetinchem, Maastricht, and Amsterdam) | No evidence of a dose-response relationship. | |||
| Baseline surveys from 1994 to 1997, average response rate 45%; Mean follow-up period 9.8 years. | Adjustment: age, sex, other types of physical activity (both occupational and leisure-time), smoking, alcohol consumption, education. |
Literature data: Direct costs from the public healthcare payer’s perspective.
| Direct costs from the public healthcare payer’s perspective | Description of the study | Study population | Year data were collected & Setting | Average annual healthcare direct costs per patient: | Reference |
|---|---|---|---|---|---|
|
| To estimate the prevalence and direct costs from the public healthcare payer’s perspective of pharmacologically-treated diabetes in Italy; 10-year longitudinal analysis of prevalence, incidence and direct costs (drug use, inpatient and outpatient activities) for the National Health Service (NHS) of pharmacologically-treated diabetes in 22 Italian Local Health Districts (ARNO observatory, population-oriented database). | 311,979 individuals | 2006; Italy (22 Local Health Districts) | €2,589 (95% CI, 2,584–2,594) | Marchesini et al. 2011 [ |
|
| To estimate economic burden of hospitalized events of Acute Myocardial Infarction; Study population: all subjects admitted because of first acute myocardial infarction in Lombardy Region in 2003, followed-up until December 31, 2005; Direct costs from the Italian National Health Service (NHS) perspective (drug use, inpatient and outpatient activities). | 12,049 individuals | 2003; Italy (Lombardy Region) | 1st year: €9,136 (SE 123.48); (Hospitalization & acute phase: €6,022) | Mantovani et al. 2011 [ |
| 2nd and 3rd year: €2,100 (SE 57.94) | |||||
| Cost-effectiveness analysis of preventive treatment with ramipril in patient at high risk of cardiovascular events; Direct costs from the Italian National Health Service (NHS) perspective (drug use, inpatient and outpatient activities); Resources involved in each event/activity were estimated using the modified Delphi technique with a panel of six clinicians. | 1,000 individuals on ramipril; 1,000 individuals on placebo (based on the HOPE trial, 9,297 individuals) | 2004; Italy | 1st year: €7,504; (Hospitalization: €4,093) | Capri & Perlini 2005 [ | |
| subsequent years after the 1st one: €1,795 | |||||
|
| To estimate stroke’s direct costs and productivity losses in Italy from a societal perspective; Prospective incidence-based observational multicentre cost of illness study (EcLIPSE study); Study population: patients admitted because of acute first-ever stroke in 11 Italian hospitals; Costs and outcomes at patients’ enrolment, and at 3, 6 and 12 months after discharge, using a bottom-up approach; Hospital selection: to represent current geographical distribution in Italy and difference in structure and organization (level of care intensity and specificity)- 3 Stroke Units, 4 neurology wards, 4 medicine wards. | 449 individuals | 2005; Italy (11 Hospitals; 3 Stroke Units, 4 neurology wards, 4 medicine wards) | 1st year: €7,611; (Hospitalization & acute phase: €3,252, First 6 months: €6,111) | Gerzeli et al. 2005 [ |
| Cost-effectiveness analysis of preventive treatment with ramipril in patient at high risk of cardiovascular events; Direct costs from the Italian National Health Service (NHS) perspective (drug use, inpatient and outpatient activities); Resources involved in each event/activity were estimated using the modified Delphi technique with a panel of six clinicians. | 1,000 individuals on ramipril; 1,000 individuals on placebo (based on the HOPE trial, 9,297 individuals) | 2004; Italy | 1st year: €17,318 (Hospitalization: €2,751) | Capri & Perlini 2005 [ | |
| subsequent years after the 1st one: €1,233 | |||||
|
| To assess heart failure prevalence, hospitalization rate, adherence to guidelines and social costs; Analysis of heart failure social costs using a retrospective “bottom-up” approach; Healthcare direct costs: drug use, inpatient and outpatient activities. | 116 individuals | 2001; Italy (Veneto Region) | €3,042 | Valle et al. 2006 [ |
Health economic assessment model data.
| Selected health outcomes | Natural history of selected health outcomes | Average annual cost per patient (€, 2013 value) | ||||
|---|---|---|---|---|---|---|
| 1st year | 2–5° year | 6–10° year | 1st year | 2nd year | 3–10° year | |
|
| M: 0.67% | M: 0.67% | M: 0.67% | €3,015; Marchesini et al. 2011 [ | €3,015; Marchesini et al. 2011 [ | €3,015; Marchesini et al. 2011 [ |
|
| 28-day M: 4.2% | M: 1.7% | M: 2.3% | Hospitalization & 1° month: €6,290; Mantovani et al. 2011 [ | €2,180; Capri & Perlini 2005 [ | €2,180; Capri & Perlini 2005 [ |
| 2–12° month M: 3.6% | 2–12° months: €9,540; Mantovani et al. 2011 [ | |||||
| HF: 17.9% | HF: 1.0% | HF: 1.0% | ||||
|
| 28-day M: 10.2% | M: 3.5% | M: 3.5% | Hospitalization & 1° month: €4,220; Gerzeli et al. 2005 [ | €2,470; Gerzeli et al. 2005 [ | €1,500; Capri & Perlini 2005 [ |
| 2–6° month M: 5.2% | 2–6° months: €3,715; Gerzeli et al. 2005 [ | |||||
| 6–12° month M: 2.4% | 6–12° months: €1,945; Gerzeli et al. 2005 [ | |||||
|
| M: 2.0% | M: 2.0% | M: 2.4% | €4,035; Valle et al. 2006 [ | €4,035; Valle et al. 2006 [ | €4,035; Valle et al. 2006 [ |
|
| M: 5.0% | M: 3.3% | M: 3.3% | €4,035; Valle et al. 2006 [ | €4,035; Valle et al. 2006 [ | €4,035; Valle et al. 2006 [ |
M: all-cause mortality
HF: Heart failure incidence following AMI
Fig 1Schematic representation of first 4 years’ model: type 2 diabetes.
Fig 3Schematic representation of first 4 years’ model: stroke.
Exposure to road traffic accidents and deaths by means of transportation (assuming 232 working/education days).
| Rate per billion passenger minutes travelled | Risk Ratio | ||||
|---|---|---|---|---|---|
| Bicycle | Car | Motorcycle, moped or scooter | bicycle/car | bicycle/ motorcycle, moped or scooter | |
|
| 3004.9 | 6219.3 | 9730.8 | 0.48 | 0.31 |
|
| 6.4 | 4.6 | 39.1 | 1.39 | 0.16 |
Road traffic accidents and deaths by means of transportation, 2008–2010 Municipality of Florence data and cycling promotion scenario analysis.
| Road traffic accidents | Road traffic deaths | |||||
|---|---|---|---|---|---|---|
| 2008–2010 data, annual average [ | Scenario 1 | Scenario 2 | 2008–2010 data, annual average [ | Scenario 1 | Scenario 2 | |
|
| 315 | 664 | 1,013 | 0.7 | 1.4 | 2.1 |
|
| 4,072 | 3,618 | 3,165 | 3.0 | 2.7 | 2.3 |
|
| 2,652 | 2,231 | 1,809 | 10.7 | 9.0 | 7.3 |
|
| 537 | 537 | 537 | 6.3 | 6.3 | 6.3 |
|
| 7,576 | 7,050 | 6,524 | 20.7 | 19.4 | 18.1 |
|
| -526 (-6.9%) | -1,051 (-13.9%) | -1.3 (-6.2%) | -2.6 (-12.5%) | ||
Model assumptions, key parameters and sensitivity analysis.
| Model assumptions and key parameters | Main analysis | Sensitivity analysis |
|---|---|---|
|
| Transfers of up to 15 minutes: | Transfers of up to 15 minutes: |
| Scenario 1: 25% | Scenario 1: 20–30% | |
| Scenario 2: 50% | Scenario 2: 40–60% | |
| Transfers between 16 and 30 minutes: | Transfers between 16 and 30 minutes: | |
| Scenario 1: 15% | Scenario 1: 10–20% | |
| Scenario 2: 30% | Scenario 2: 25–35% | |
|
| 75% | 50–100% |
|
| Scenario 1: 1 year | Scenario 1: 0–3 years |
| Scenario 2: 3 years | Scenario 2: 1–5 years | |
|
| 5 years | 3–8 years |
|
| 5% | 3.5% |
|
| HR | upper and lower bounds of the 95% CI |
|
| literature data, adjusted to €2013 | -/+ 20% |
Individuals commuting to work or school in Florence, by mode of transport and travel time, 2011 population census data and cycling promotion scenario analysis (rounded numbers).
| ≤ 15 minutes | 16–30 minutes | > 30 minutes | Total | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2011 data | Scenario 1 | Scenario 2 | 2011 data | Scenario 1 | Scenario 2 | 2011 data, Scenario 1, and Scenario 2 | 2011 data | Scenario 1 | Scenario 2 | |
|
| 28,278 | 5,343 | 722 | 34,343 | ||||||
|
| 7,707 | 18,792 | 29,878 | 5,116 | 11,322 | 17,527 | 795 | 13,617 | 30,909 | 48,200 |
|
| 26,397 | 19,798 | 13,200 | 27,008 | 22,957 | 18,906 | 12,465 | 65,873 | 55,220 | 44,571 |
|
| 17,944 | 13,458 | 8,973 | 14,363 | 12,209 | 10,054 | 2,028 | 34,336 | 27,695 | 21,055 |
|
| 3,651 | 13,697 | 14,295 | 31,643 | ||||||
|
| 662 | 715 | 303 | 1,680 | ||||||
|
| 84,637 | 66,242 | 30,613 | 181,491 | ||||||
Scenario 1: Less ambitious cycling promotion target
Scenario 2: Optimistic cycling promotion target
NCD prevention and healthcare direct costs savings (5% discount rate per year) based on Florence cycling promotion scenarios over a ten-year period (2013–2022).
| Incident cases prevented over a 10-year period (2013–2022) | Premature deaths prevented over a 10-year period (2013–2022) | Maximum decrease in annual incidence | Potential savings from the public healthcare payer’s perspective, discounted by 5% per year (€, 2013 value) | |||||
|---|---|---|---|---|---|---|---|---|
| Scenario 1 | Scenario 2 | Scenario 1 | Scenario 2 | Scenario 1 | Scenario 2 | Scenario 1 | Scenario 2 | |
|
| 280 (211–350) | 549 (413–685) | 4 (3–5) | 8 (6–9) | 1.7% (1.3%-2.1%) | 3.3% (2.5%-4.1%) | 2,714,296 (2,041,530–3,386,910) | 5,172,991 (3,890,926–6,454,903) |
|
| 51 (38–64); HF: 7 (5–9) | 100 (75–124); HF: 14 (11–18) | 19 (14–24) | 37 (28–47) | 0.8% (0.6%-1.0%) | 1.7% (1.3%-2.1%) | 753,697 (566,886–940,466) | 1,479,008 (1,112,453–1,845,521) |
|
| 51 (38–63) | 99 (75–124) | 19 (14–24) | 37 (28–46) | 0.8% (0.6%-1.0%) | 1.7% (1.3%-2.1%) | 540,044 (406,189–673,869) | 1,060,007 (797,296–1,322,687) |
Scenario 1: Less ambitious cycling promotion target
Scenario 2: Optimistic cycling promotion target
HF: Heart failure
Worst- and best-case cycling promotion scenarios are given in brackets
* Yearly reduction in incident cases at full effect, 100% of regular commuter cyclists enjoying better health due to their regular physical activity.
Fig 4Potential yearly discounted savings on healthcare direct costs by year and health outcome, 5% discount rate (€, 2013).
Scenario 1: Less ambitious cycling promotion target; Scenario 2: Optimistic cycling promotion target.
Fig 5Discounted savings over a 10-year period (2013–2022)—Sensitivity analyses’ results.
Scenario 1: Less ambitious cycling promotion target; Scenario 2: Optimistic cycling promotion target.